

STUDY TITLE	CSL112-3001, the AEGIS II Study: A Phase 3. Multicenter, Double- blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome.
STUDY POPULATION	Subjects who present with STEMI or NSTEMI (managed with percutaneous coronary intervention [PCI] or medically managed), with documented evidence of multivessel coronary artery disease and at least 1 other established risk factor for recurrent CV events, were selected as the study population because they are all at high risk for recurrent MACE after experiencing an index event.
PRINCIPAL INVESTIGATOR	Dato' Sri Dr. Azhari Rosman, Senior Consultant Cardiologist / Director of Customer Experience, Cardiology Department, IJNSB
STUDY COORDINATOR	Noor Syamira Contact number : 03 – 2617 8200 Ext: 3133
START DATE	12 Jun 2019
END DATE	06 February2023